What is the drug anlotinib used for?

iebpharma360

Anlotinib, also known by its International Nonproprietary Name (INN) as Anlotib, is a novel small-molecule multi-targeted tyrosine kinase inhibitor (TKI) that has shown promise in the treatment of various types of cancers. With a molecular weight of approximately 493.6 g/mol, Anlotinib exerts its therapeutic effects by selectively inhibiting the activities of vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), fibroblast growth factor receptors (FGFR), and other kinases involved in tumor angiogenesis and progression.

The recommended dosage of Anlotinib is typically 12 mg once daily, administered orally. This dosage may be adjusted Anlotinib INN 12 Mg (Anlotib) based on individual patient factors such as tolerance and response to treatment. Anlotinib is commonly used as a second- or third-line treatment option for patients with advanced non-small cell lung cancer (NSCLC), metastatic soft tissue sarcoma (STS), and other solid tumors.

Clinical studies have demonstrated the efficacy of Anlotinib in prolonging progression-free survival (PFS) and overall survival (OS) in patients with advanced cancers. In a Phase III trial involving patients with advanced NSCLC who had progressed after at least two lines of chemotherapy, Anlotinib significantly improved median PFS compared to placebo. Similar results were observed in clinical trials involving patients with STS and other solid tumors.




In addition to its efficacy, Anlotinib is generally well-tolerated, with manageable adverse effects. Common side effects include hypertension, hand-foot syndrome, fatigue, decreased appetite, and proteinuria. Close monitoring of blood pressure and liver function tests is recommended during treatment with Anlotinib to promptly identify and manage any potential adverse reactions.

Anlotinib represents a valuable addition to the armamentarium of targeted therapies available for the treatment of advanced cancers. Its multi-targeted kinase inhibition offers the potential for broad-spectrum antitumor activity, making it a promising option for patients who have exhausted standard treatment options. Ongoing research continues to explore the optimal use of Anlotinib across different cancer types and in combination with other therapeutic agents, with the aim of further improving outcomes for patients with advanced malignancies.